Immunocore Holdings plc
Immunocore Holdings plc, a pioneering biotechnology company headquartered in Great Britain, is at the forefront of developing innovative T cell receptor (TCR) therapies for cancer and other serious diseases. Founded in 2008, Immunocore has made significant strides in the biopharmaceutical industry, particularly with its proprietary ImmTAC platform, which harnesses the power of T cells to target and destroy cancer cells. With a strong operational presence in Europe and North America, Immunocore has established itself as a leader in the field of immuno-oncology. The company’s flagship product, tebentafusp, has garnered attention for its unique mechanism of action and has received regulatory approvals for treating metastatic uveal melanoma. Recognised for its commitment to advancing cancer treatment, Immunocore continues to push the boundaries of science, positioning itself as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Immunocore Holdings plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Immunocore Holdings plc's score of 25 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Immunocore Holdings plc's reported carbon emissions
In 2023, Immunocore Holdings plc reported no specific carbon emissions data, indicating a lack of disclosed Scope 1, 2, or 3 emissions figures. The company’s revenue for the year was approximately USD 249.4 million. In 2022, the revenue was about USD 174.4 million, but again, no emissions data was disclosed for that year. Immunocore has not set any reduction targets or climate pledges, and there are no initiatives reported under the Science Based Targets initiative (SBTi) or other climate frameworks. The absence of emissions data suggests that the company may be in the early stages of developing its climate strategy or reporting practices. As of now, Immunocore does not inherit emissions data from any parent or related organizations, indicating that its climate commitments and emissions reporting are independent. The company is encouraged to establish measurable targets and disclose emissions data to align with industry standards and enhance transparency in its climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Immunocore Holdings plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
